Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on first‐line oral therapy for type 2 diabetes: A claims‐based observational cohort study

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2021-12, Vol.23 (12), p.2741-2751
• Main Authors: Olufade, Temitope, Jiang, Like, Israni, Rubeen, Huang, Joanna, Gosmanov, Aidar R.
• Format: Article
• Language: English
• Subjects: Adult; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; chronic kidney disease; Cohort analysis; Cohort Studies; Congestive heart failure; Delivery of Health Care; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diabetic nephropathy; Diagnosis; Health care; Health services utilization; Heart failure; Humans; Kidney diseases; Observational studies; observational study; Patients; Renal Insufficiency, Chronic - complications; Renal Insufficiency, Chronic - epidemiology; Resource utilization; Retrospective Studies; sodium‐glucose co‐transporter‐2 inhibitor; type 2 diabetes
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14530

Aim To examine incident cardiovascular disease (CVD) and chronic kidney disease (CKD) diagnosis and associated healthcare resource utilization (HCRU) in a real‐world population of patients with type 2 diabetes (T2D) initiating first‐line oral antidiabetes drug (OAD) therapy. Materials and Methods Adults with T2D without CVD/CKD initiating first‐line OAD therapy from 2008 to 2018 IBM MarketScan claims data were included. Incident CVD/CKD diagnoses following OAD initiation and first diagnosis type were assessed. Risk of incident diagnosis of heart failure (HF) among patients with CKD and of CKD among patients with HF was evaluated. HCRU and costs were compared for the 12 months before and after the first CVD/CKD diagnosis. Results Of 12 286 016 patients, 1 286 287 met all the inclusion criteria. During follow‐up (mean 752 days), 205 865 (16.0%) patients had CVD/CKD diagnoses; the most common first diagnosis was the composite cardiorenal outcome of HF and/or CKD (64.6%). Most first diagnoses were within 2 years of OAD initiation. For HF and CKD, diagnosis of one was associated with increased risk of subsequent diagnosis of the other (both P